Literature DB >> 34689313

Hypertriglyceridemia is a risk factor for treatment failure in patients with peritoneal dialysis-related peritonitis.

Ya-Juan Huang1, Zong-Pei Jiang1, Ja-Fan Zhou1, Xing Zhang1, Li-Ping Xiong1, Meng-Jun Liang1, Hong-Rui Shi1, Ning Su2, Rui Zhang3.   

Abstract

OBJECTIVE: Disorders of triglycerides (TG) are common in patients with peritoneal dialysis (PD). Hypertriglyceridemia has been demonstrated in various infections. The association between triglycerides and the outcomes of peritoneal dialysis-related peritonitis (PDRP) was investigated in this study.
METHODS: We retrospectively investigated patients with PDRP from January 1, 2013 to October 31, 2020. Hypertriglyceridemia was defined as triglycerides ≥ 1.7 mmol/L. PDRP episodes were divided into two groups: hypertriglyceridemia and normal levels of triglycerides. The clinical and laboratory baseline data of the two groups were collected and compared. The association between triglycerides and treatment failure was analyzed by logistic regression analysis.
RESULTS: Ninety episodes in 66 patients were recorded in our center. Hypertriglyceridemia occurred in 38% (34/90) of episodes. Twenty-five episodes were not cured in 90 episodes (27.8%, 25/90). The levels of thrombocytes, high-sensitivity C-reactive protein (hs-CRP), low-density lipoprotein cholesterol (LDL-C) and glycated hemoglobin, were higher in hypertriglyceridemia episodes of PDRP at baseline. The bacterial classification was different between elevated triglyceride group and normal triglyceride group. Adjusted for age, duration of dialysis, residual renal function, diabetes, thrombocytes, hs-CRP, serum albumin, cholesterol, HDL-C, LDL-C, intact parathyroid hormone (iPTH), glycated hemoglobin and spectrum of bacteria, hypertriglyceridemia were associated significantly with treatment failure of PDRP in our study (OR 3.416, 95% CI 1.223-9.540 p < 0.05).
CONCLUSION: Hypertriglyceridemia at baseline was an independent risk factor for treatment failure of PDRP.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Infection; Peritoneal dialysis; Peritoneal dialysis-related peritonitis; Triglyceride

Mesh:

Substances:

Year:  2021        PMID: 34689313     DOI: 10.1007/s11255-021-03027-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  2 in total

1.  Hemodialysis versus peritoneal dialysis: an observational study in two international centers.

Authors:  Renhua Lu; Carla Estremadoyro; Xiaohuan Chen; Mingli Zhu; Leonardo C Ribeiro; Yucheng Yan; Alessandra Brendolan; Wei Fang; Carlo Crepaldi; Zhaohui Ni; Leyi Gu; Claudio Ronco
Journal:  Int J Artif Organs       Date:  2017-11-08       Impact factor: 1.595

Review 2.  Metabolic consequences of peritoneal dialysis treatment.

Authors:  M Gallieni; C Musetti; A Granata; L Olivi; S Bertoli
Journal:  Panminerva Med       Date:  2009-09       Impact factor: 5.197

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.